

Technology Appraisal Committee Meeting (Committee [A])

Minutes: [Confirmed]

Date and Time: Tuesday 8 August 2017

Venue:

National Institute for Health and Care Excellence
10 Spring Garden
London
SW1A 2BA

Present:		
1.	Chair Jane Adam	Present for all notes
2.	Professor Iain Squire	Present for all notes
3.	Dr Graham Ash	Present for all notes
4.	Dr Rita Faria	Present for all notes
5.	Dr Rachel Hobson	Present for all notes
6.	Dr Anne McCune	Present for all notes
7.	Dr Brian Shine	Present for all notes
8.	Dr Ian Bernstein	Present for all notes
9.	Mrs Sarah Parry	Present for all notes
10.	Ms Pamela Rees	Present for all notes
11.	Ms Ellen Rule	Present for all notes
12.	Dr Paul Robinson	Present for all notes
13.	Mr David Evans	Present for all notes
14.	Mr Stephen Sharp	Present for all notes
15.	Professor Olivia Wu	Present for all notes
16.	Dr John Watkins	Present for all notes
17.	Dr Nerys Woolacott	Present for all notes
18.	Professor John McMurray	Present for all notes

In attendance:

Meindert Boysen	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for all notes
Thomas Feist	Project Manager, National Institute for	Present for all notes

Health and Care
Excellence

Marcia Miller	Technology Appraisal Administrator, National Institute for Health and Care Excellence	Present for all notes
Hamish Lungaria	Technical Analyst, National Institute for Health and Care Excellence	Present for all notes
Zoe Charles	Technical Adviser, National Institute for Health and Clinical Excellence	Present for all notes
Mrs Gwyneth Fraser	Patient expert nominated by Breast Cancer Now	Present for notes 7 to 15
Catherine Priestly	Patient expert nominated by Breast Cancer Now	Present for notes 7 to 15
Dr Daniel Rea	Nominated by RCP	Present for notes 7 to 15
Keith Cooper	ERG, Southampton Health Technology Assessment Centre	Present for notes 7 to 15
Joanne Picot	ERG, Southampton Health Technology Assessment Centre	Present for notes 7 to 15
Neelam Kalita	ERG, Southampton Health Technology Assessment Centre	Present for notes 7 to 15
Mr Pete Fraser	Patient carer	Present for all notes 7 to 15
Helen Barnett	NICE, Appraisal Editors	Present for all notes
Minal Bakhai	Committee A Member	
Chloe Kastoryano	NICE, PPIP	Present for notes
Min ven teo	NICE Scholar	Present for notes

Presentations	Notes
Olu Onyimadu	NICE, IP
Wendy Gainsford	ERG Team
Joshua South	NICE, Corporate Office
Adam Storrow	NICE, Implementation

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951]
2. The Chair informed the Committee of the non-public observers at this meeting: Mr Peter Fraser, Helen Barnett, Minal Bakhai, Min ven teo, Chloe Kastoryano and Joshua South
- 3.
4. Rui Martins, Olu Onyimadu, Wendy Gainsford and Adam Storrow
5. Apologies were received from

Notes from the last meeting

6. The minutes of the last meeting were agreed with no changes.

Appraisal of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951]

Part 1 – Open session

7. The Chair welcomed the invited experts: Keith Cooper, Mrs Gwyneth Fraser, Neelam Kalita, Joanne Picot, Dr Daniel Rea and Catherine Priestly to the meeting and they introduced themselves to the Committee.
8. The Chair welcomed company representatives from AstraZeneca to the meeting.
9. The Chair asked all Committee members to declare any relevant interests
 - 9.1. Dr Jane Adam, Dr Graham, Dr Rita Faria, Dr Rachel Hobson, Dr Anne McCune, Dr Brian Shine, Dr Ian Bernstein, Mrs Sarah Parry, Ms Pamela

Rees, Ms Ellen Rule, Dr Paul Robinson, Mr David Evans, Mr Stephen Sharp, Professor Olivia Wu, Dr John Watkins, Dr Nerys Woolacott and Professor John McMurray all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951]

- 9.2. Professor John McMurray declared a non-personal specific financial interest as he has his university receives funding from company/comparator for heart disease trials.
 - 9.2.1 It was agreed that this declaration would not prevent Professor John McMurray from participating in this section of the meeting.
- 9.3. Dr Iain Squire declared a non-personal specific financial interest as he has received honoraria from Novartis for participation in advisory Boards and Educational events. My Department is in receipt of financial support to fund research from Novartis
 - 9.3.1 It was agreed that this declaration would not prevent Professor Iain Squire from participating in this section of the meeting.

10. The Chair asked all NICE Staff to declare any relevant interests.

- 10.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951]

11. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

- 11.1. Keith Cooper, Mrs Gwyneth Fraser, Joanne Picot, Neelam Kalita and Catherine Priestly declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951].
- 11.2. Dr Daniel Rea declared a personal non-specific financial interest for teaching AstraZeneca Sales Force on management of adjunct breast cancer and Honoria paid to charities
 - 11.2.1. It was agreed that this declaration would not prevent Dr Daniel Rea from participating in this section of the meeting

12. The Chair introduced the lead team, Dr Rachel Hobson and Professor Olivia Wu who gave presentations on the clinical effectiveness and cost effectiveness of

Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951].

13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
14. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.
15. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. Discussion on confidential information continued. This information was supplied by the company.
17. The Committee continued to discuss the clinical and cost effectiveness of Fulvestrant for untreated hormone-receptor positive locally advanced or metastatic breast cancer [ID951].
18. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

19. Tuesday 5 September 2017, 10am at Prospero House, 241 Borough High Street, SE1 1GA